Schroder Investment Management Group cut its stake in shares of PerkinElmer, Inc. (NYSE:PKI) by 18.5% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 587,548 shares of the medical research company’s stock after selling 133,273 shares during the period. Schroder Investment Management Group owned approximately 0.53% of PerkinElmer worth $56,604,000 at the end of the most recent reporting period.
A number of other institutional investors also recently added to or reduced their stakes in the stock. Sumitomo Mitsui Trust Holdings Inc. raised its position in shares of PerkinElmer by 1,019.5% in the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 521,309 shares of the medical research company’s stock valued at $50,223,000 after purchasing an additional 474,741 shares in the last quarter. Allianz Asset Management GmbH raised its position in shares of PerkinElmer by 76.0% in the 2nd quarter. Allianz Asset Management GmbH now owns 448,006 shares of the medical research company’s stock valued at $43,161,000 after purchasing an additional 193,515 shares in the last quarter. Swiss National Bank raised its position in shares of PerkinElmer by 78.3% in the 2nd quarter. Swiss National Bank now owns 361,400 shares of the medical research company’s stock valued at $34,817,000 after purchasing an additional 158,700 shares in the last quarter. First Trust Advisors LP raised its position in shares of PerkinElmer by 4,054.9% in the 2nd quarter. First Trust Advisors LP now owns 137,277 shares of the medical research company’s stock valued at $13,225,000 after purchasing an additional 133,973 shares in the last quarter. Finally, Artisan Partners Limited Partnership raised its position in shares of PerkinElmer by 42.3% in the 1st quarter. Artisan Partners Limited Partnership now owns 408,941 shares of the medical research company’s stock valued at $39,406,000 after purchasing an additional 121,552 shares in the last quarter. 95.20% of the stock is currently owned by hedge funds and other institutional investors.
In other news, Director Alexis P. Michas sold 2,000 shares of the company’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $82.56, for a total value of $165,120.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 1.80% of the company’s stock.
PKI traded down $0.72 during trading on Wednesday, reaching $84.05. 7,773 shares of the company were exchanged, compared to its average volume of 575,917. PerkinElmer, Inc. has a 52 week low of $71.83 and a 52 week high of $103.00. The stock has a market cap of $9.61 billion, a P/E ratio of 23.28, a PEG ratio of 1.60 and a beta of 1.29. The firm has a 50 day moving average of $83.32 and a 200 day moving average of $90.95. The company has a current ratio of 1.89, a quick ratio of 1.31 and a debt-to-equity ratio of 0.84.
PerkinElmer (NYSE:PKI) last announced its quarterly earnings data on Monday, July 29th. The medical research company reported $1.00 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.01 by ($0.01). The firm had revenue of $722.50 million during the quarter, compared to analyst estimates of $729.10 million. PerkinElmer had a net margin of 9.01% and a return on equity of 16.07%. The company’s quarterly revenue was up 2.7% compared to the same quarter last year. During the same quarter last year, the company earned $0.91 EPS. As a group, analysts forecast that PerkinElmer, Inc. will post 4.05 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 8th. Stockholders of record on Friday, October 18th will be issued a $0.07 dividend. The ex-dividend date of this dividend is Thursday, October 17th. This represents a $0.28 annualized dividend and a dividend yield of 0.33%. PerkinElmer’s dividend payout ratio (DPR) is 7.76%.
PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services.
Featured Article: Initial Coin Offerings entail a high degree of risk
Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.